Research Reveals Global Growth of Secure DevOps
24.3.2021 05:23:00 EET | Business Wire | Press release
New research from Secure Code Warrior ®, the global secure coding company, has revealed an attitudinal shift in the software development industry, with organisations bucking traditional practices for DevOps and Secure DevOps.
The global survey of professional developers and their managers found seven in 10 organisations (70%) recognise the importance of secure coding practices, with results indicating an industry-wide shift from reaction to prevention is underway.
Dr. Matias Madou, Chief Technology Officer and Co-Founder at Secure Code Warrior, said, “We are seeing a fundamental shift in mindsets across the world, as the industry slowly moves from reactive, band-aid solutions rolled out after a breach, to the proactive and human-led practice of writing quality software that is intrinsically free from vulnerabilities right from the very first keystroke.”
“This research shows that ‘secure code’ is becoming synonymous with ‘quality code’ within software development, and security is becoming the responsibility of development teams and leaders—not just AppSec professionals,” he said.
Secure coding seen as ‘reactive’
Reactive practices like using tools on deployed applications and manually reviewing code for vulnerabilities were the top two practices respondents associated with coding securely. However, a proactive shift in mindset was evidenced across the globe, with more than half (55%) of the developers surveyed also recognising secure coding as the active, ongoing practice of writing software protected from vulnerabilities.
Managers and developers are misaligned
Over half (55%) of managers surveyed said secure coding was practised and integrated throughout the entire development process, compared to only 43% of developers. Conversely, 36% of developers consider secure coding during development but not the design phase, as opposed to under one-third (32%) of managers.
Secure code an increasing indicator of success
While those surveyed identified ‘application performance’ and ‘functionality and features’ as the most common success metrics within software development (67% and 62% respectively), almost four in five (79%) respondents said the importance of ‘secure code’ was growing in prominence.
Application security is shifting
Almost half of respondents (46%) said development leads and teams should be responsible for application security rather than AppSec teams (24%). Over eight in 10 (81%) developers surveyed said they were accountable for any vulnerable code produced.
Developers motivated to upskill
‘Increased productivity and efficiency’, ‘curiosity’ and ‘avoiding problems caused by insecure code’ were identified as the leading intrinsic motivators to learn secure coding (20%, 14% and 11% respectively). Despite only 10% of respondents listing career advancement as a personal motivator, four in five (81%) managers were more likely to hire talent with secure coding skills.
More training is needed
91% of managers surveyed said they faced greater than average difficulty when implementing secure coding practices within their organisation, despite the overwhelming majority of respondents (97%) believing they were sufficiently trained. Perhaps, this is because almost nine in 10 (88%) developers surveyed said coding securely was challenging.
Madou added, “With OWASP’s Top 10 software vulnerabilities causing more security breaches over the past two decades than any others, now is the time for businesses to upskill developers to gain the knowledge and skills needed to stamp out insecure code and prevent issues from occurring in the first place.”
“Code is at the heart of everyday interactions, and Secure Code Warrior is focused on championing security-skilled developers who can create amazing, safe software for our connected world.”
To gain early access to the report, ‘Shifting from reaction to prevention: The changing face of application security 2021’, register your interest at scw.buzz/earlyaccess
Methodology
Secure Code Warrior® commissioned Evans Data Corporation, the market intelligence leader within the IT industry, to conduct a global survey of developers and decision-makers actively engaged in software development. In August 2020, 400 respondents were surveyed across North America, India, the United Kingdom, Europe, Australia, New Zealand and South-East Asia.
About Secure Code Warrior
Secure Code Warrior is the developer-chosen solution for growing powerful secure coding skills. By making secure coding a positive and engaging experience for developers as they increase their software security skills, our human-led approach uncovers the secure developer inside every coder, helping development teams ship quality code faster.
Through inspiring a global community of security-conscious developers to embrace a preventative secure coding approach, our mission is to pioneer a people-first solution to security upskilling, stamping out poor coding patterns for good. Learn more at securecodewarrior.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323006113/en/
Contact information
For media enquiries, to access the full report or arrange an interview:
Carly Ryan, Hotwire
E: securecodewarrior@hotwireglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
